Citation: M. Fishbein et B. Jarvis, Failure to find a behavioral surrogate for STD incidence - What does it really mean?, SEX TRA DIS, 27(8), 2000, pp. 452-455
Citation: Km. Hvizdos et B. Jarvis, Budesonide inhalation suspension - A review of its use in infants, children and adults with inflammatory respiratory disorders, DRUGS, 60(5), 2000, pp. 1141-1178
Citation: A. Markham et B. Jarvis, Inhaled salmeterol/fluticasone propionate combination - A review of its use in persistent asthma, DRUGS, 60(5), 2000, pp. 1207-1233
Citation: Cj. Dunn et B. Jarvis, Dalteparin: an update of its pharmacological properties and clinical efficacy in the prophylaxis and treatment of thromoembolic disease. (vol 60, pg 203, 2000), DRUGS, 60(4), 2000, pp. 719-719
Citation: Cj. Dunn et B. Jarvis, Dalteparin - An update of its pharmacological properties and clinical efficacy in the prophylaxis and treatment of thromboembolic disease, DRUGS, 60(1), 2000, pp. 203-237
Citation: K. Simpson et B. Jarvis, Fexofenadine: A review of its use in the management of seasonal allergic rhinitis and chronic idiopathic urticaria (vol 59, pg 301, 2000), DRUGS, 59(5), 2000, pp. 1089-1089
Citation: K. Simpson et B. Jarvis, Fexofenadine - A review of its use in the management of seasonal allergic rhinitis and chronic idiopathic urticaria, DRUGS, 59(2), 2000, pp. 301-321
Citation: B. Jarvis et D. Faulds, Lamivudine: a review of its therapeutic potential in chronic hepatitis B. (vol 58, pg 101, 1999), DRUGS, 58(4), 1999, pp. 587-587
Citation: B. Jarvis et D. Faulds, Inhaled fluticasone propionate - A review of its therapeutic efficacy at dosages <= 500 mu g/day in adults and adolescents with mild to moderate asthma, DRUGS, 57(5), 1999, pp. 769-803